Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
PRIMARY STUDY OBJECTIVES
- To evaluate the efficacy of the combination of bortezomib, dexamethasone, with and
without DOXIL, followed by high-dose cyclophosphamide as a therapy for two different
subsets of multiple myeloma patients:
1. Patients post first line therapy
2. Patients with relapsed/refractory disease who are bortezomib-naïve
- To evaluate the safety of the combination of bortezomib and dexamethasone, with and
without DOXIL, followed by high-dose cyclophosphamide as therapy for patients with
multiple myeloma.
SECONDARY STUDY OBJECTIVES
- To evaluate the role of the combination of bortezomib dexamethasone, with and without
DOXIL, followed by high-dose cyclophosphamide on the ability to collect > 10 x 106 CD34+
cells/kg in < 7 collections (for both subsets of multiple myeloma patients).
- To evaluate the survival of patients who receive the combination of bortezomib
dexamethasone, with and without DOXIL, followed by high-dose cyclophosphamide (for both
subsets of patients).